Navigation Links
Huntington's disease deciphered
Date:6/14/2009

Researchers at the University of Illinois at Chicago College of Medicine have discovered how the mutated huntingtin gene acts on the nervous system to create the devastation of Huntington's disease. The report of their findings is available in Nature Neuroscience online.

The researchers were able to show that the mutated huntingtin gene activates a particular enzyme, called JNK3, which is expressed only in neurons and, further, to show what effect activation of that enzyme has on neuron function.

Huntington's disease is an adult onset neurodegenerative disease marked by progressive mental and physical deterioration. It has been known for more than a decade that everyone who develops the disease has mutations in a particular gene, called huntingtin, according to Scott Brady, professor and head of anatomy and cell biology at the UIC College of Medicine.

"There are several puzzling aspects of this disease," said Brady, who is co-principal investigator on the study. "First, the mutation is there from day one. How is it that people are born with a perfectly functioning nervous system, despite the mutation, but as they grow up into their 30s and 40s they start to develop these debilitating symptoms? We need to understand why the protein is bad at 40 but it wasn't bad at 4."

The second problem, according to Brady, is that the gene is expressed not just in the nervous system but in other parts of the body. However, the only part of the body that is affected is the nervous system. Why are neurons being affected?

Brady, Gerardo Morfini, assistant professor of anatomy and cell biology at UIC and co-principal investigator of the study, and their colleagues began looking for a mechanism that could explain all the pieces of the puzzle. They found that at extremely low concentrations, huntingtin was a potent inhibitor of axonal transport, the system within the neuron that shuttles proteins from the cell body where they are
'/>"/>

Contact: Jeanne Galatzer-Levy
jgala@uic.edu
312-996-1583
University of Illinois at Chicago
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. Gender, coupled with diabetes, affects vascular disease development
3. Study links cat disease to flame retardants in furniture and to pet food
4. Humans fostering forest-destroying disease
5. Emerging (disease) markets
6. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
7. Clemson chemists discover new way antioxidants fight debilitating diseases
8. Finding that 1-in-a-billion that could lead to disease
9. Study shows link between alcohol consumption and hiv disease progression
10. Natural chemical found in broccoli helps combat skin blistering disease
11. 60 second test could help early diagnosis of common brain diseases

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...coal-tar-based sealcoats in parking lots may be th... a USGS study. PAHs or polycyclic aromatic hydro...d tar deposits, and can have toxic effects. It,s l...dust; however, the specific sources of these PAHs ...ust from indoor areas near parking lots with coal-...
(Date:11/20/2009)... German . , In the current online issue of ...nie Eyerich and Dr. Kilian Eyerich together with t...stituto Dermopatico dell,Immacolata in Rome, prese... milestone on the way to developing new treatment ...riasis and allergic reactions and potentially also...
(Date:11/20/2009)...search Center (ERC) has been awarded a grant from ...hods of recovering and reusing the heat that would...ssion process in a carbon capture system. The goal...apture and sequestration, or storage (CCS), and th...itted into the atmosphere by coal-fired power plan...
Breaking Biology News(10 mins):From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Discovery of new type of immune cells regulating inflammation in chronic diseases 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Golden Meditech Announces Financial Year 2008 09 Annual Results 50363 1Golden Meditech Announces Financial Year 2008 09 Annual Results 50363 2Golden Meditech Announces Financial Year 2008 09 Annual Results 50363 3Global Prescription Drugs Market to Cross 24897 Billion by 2015 According to New Report by Global Industry Analysts Inc 12837 1Global Prescription Drugs Market to Cross 24897 Billion by 2015 According to New Report by Global Industry Analysts Inc 12837 2Global Prescription Drugs Market to Cross 24897 Billion by 2015 According to New Report by Global Industry Analysts Inc 12837 3Global Prescription Drugs Market to Cross 24897 Billion by 2015 According to New Report by Global Industry Analysts Inc 12837 4Mission Predisan and Jackson Healthcare 28JH 29 Partner for Medical Missions 50359 1Mission Predisan and Jackson Healthcare 28JH 29 Partner for Medical Missions 50359 2Mission Predisan and Jackson Healthcare 28JH 29 Partner for Medical Missions 50359 3
...day approved Symlin, an injectable medicine to con... diabetes. Symlin is to be used in addition to ins...te control of their blood sugars on intensive insu...py for the treatment of type 1 diabetes other than...ve several other types of oral therapies available...
... have discovered how fish have evolved over the la...nt water depths. , A research team led by Dr Mich...School of Biological Sciences, has revealed how mo...way of floating at certain water levels using a ga... the mechanism that allows fishes to keep the swim...
...Tunisia, supported by the European Commission, hig...g health in countries bordering the Mediterranean ...ortance of Euro-Mediterranean partnerships in orde...fe sciences ?in particular following the mapping o...prove scientific knowledge and approaches to impro...
Other Biology News:FDA Approves New Drug to Treat Type I and Type II Diabetes 2Scientists discover how fish evolved to float at different sea depths 2Measuring the impact of post-genomics on Mediterranean populations 2
(Date:11/20/2009)...TOLEDO recently announced that Dr. Dominique Hebra...f Process Analytical Technology (PAT) in Green Che... 2009. , (PRWEB) November...tical Technology (PAT) in Green Chemistry and Gree...ytical Technology (PAT) case studies will be prese...
(Date:11/19/2009)...swire-FirstCall/ -- Omeros Corporation (Nasdaq: O...for the third quarter ended September 30, 2009. Fo...s reported a net loss of $3.9 million, or $1.34 pe..., or $2.54 per share, for the same period in 2008.... Company reported a net loss of $15.5 million, or ...
(Date:11/19/2009)...wswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NB...g letter to its shareholders, discussing the Compa...opharmaceuticals Holdings, Inc. (CHBP), an integra...,s Republic of China. The merger gives NeoStem a c...cal Co. Ltd., CHBP,s primary operating subsidiary ...
(Date:11/19/2009)..., November 19 MONITORING FORCE Gmb... 2009 Flibanserin in the,indication treatment-rele...sease for orphan drug status designation with the ... dyskinesia is a complication of the mainstay,trea... to some of those,affected, since it may be disabl...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
...ssociates, Inc., administrator for the HealthShare...or the HealthShares(TM) Exchange-Traded Funds,toda...ng on Monday, January,7, 2008, Maxygen, Inc. (Nasd...c. (Nasdaq: ASPV ) in the HealthShares(TM) Autoim...O ) will also replace Aspreva Pharmaceutical, Inc....
...dest growth in the,traditional life science market...nities in agricultural, biodefense and molecular d...iliar waters, leading research and,advisory firm B...t,examining the marketing and media preferences of...report, "Marketing to Life Scientists: Capturing,C...
...Cerimon,Pharmaceuticals, Inc. announced today that...a newly established position, and Vice President o... a global life sciences,executive and corporate at...ical, medical device and early-stage companies in ...e, he replaces Timothy J. McBride,who will be furt...
Other Biology Technology:QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes 2Study Examines Media Preferences of Life Scientists in Applied Markets 2Study Examines Media Preferences of Life Scientists in Applied Markets 3Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing 2
Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation
...ging system for detection of very low level of lum... extreme sensitive camera to detect low level ligh...us disease research, gene expression, circadian rh... with a motor-driven camera inside the light-tight...
... sets a new standard for high performance flow cyt...strumentation, this easy-to-use benchtop system de... The BD FACSAria instrument is the first benchtop ... flow cell. This new flow cell provides superior ...
Mouse Anti-Human IFNA13 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: